Edwards Lifesciences (NYSE:EW) CFO Scott Ullem Sells 7,700 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) CFO Scott Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Edwards Lifesciences Trading Down 1.3%

Shares of NYSE EW opened at $83.18 on Wednesday. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The business has a 50-day moving average price of $81.19 and a two-hundred day moving average price of $78.88. The firm has a market capitalization of $48.27 billion, a PE ratio of 35.86, a PEG ratio of 3.79 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm’s revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Trading of Edwards Lifesciences

Several large investors have recently made changes to their positions in the stock. Allworth Financial LP raised its stake in shares of Edwards Lifesciences by 36.6% in the 3rd quarter. Allworth Financial LP now owns 5,505 shares of the medical research company’s stock valued at $428,000 after acquiring an additional 1,476 shares in the last quarter. IFP Advisors Inc grew its holdings in Edwards Lifesciences by 2.4% during the third quarter. IFP Advisors Inc now owns 6,703 shares of the medical research company’s stock valued at $521,000 after purchasing an additional 158 shares during the last quarter. Swiss Life Asset Management Ltd grew its holdings in Edwards Lifesciences by 2.9% during the third quarter. Swiss Life Asset Management Ltd now owns 153,276 shares of the medical research company’s stock valued at $11,920,000 after purchasing an additional 4,336 shares during the last quarter. Groupama Asset Managment bought a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $1,338,000. Finally, Investment Research Partners LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $494,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on EW shares. Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. UBS Group set a $92.00 price objective on Edwards Lifesciences in a research report on Friday. Mizuho boosted their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Robert W. Baird upped their target price on Edwards Lifesciences from $83.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday, December 5th. Finally, Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.09.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.